Metastatic Breast Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Roche, RemeGen, SynCore, Allarity, Byondis, Ambrx

Metastatic Breast Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape |  Roche, RemeGen, SynCore, Allarity, Byondis, Ambrx
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Metastatic Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Metastatic Breast Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic Breast Cancer Market. 

The Metastatic Breast Cancer Pipeline report embraces in-depth commercial, regulatory, and Metastatic Breast Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Metastatic Breast Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Metastatic Breast Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Metastatic Breast Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Metastatic Breast Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Metastatic Breast Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Metastatic Breast Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Breast Cancer therapeutic market.

Metastatic Breast Cancer Therapeutics Landscape

Metastatic breast cancer is made up of cells from the original tumor that developed in the breast. So if breast cancer spreads to the bone, the metastatic tumor in the bone is made up of breast cancer cells, not bone cancer cells. The main treatment for metastatic breast cancer is systemic therapy. These therapies treat the entire body. Systemic treatments may include a combination of chemotherapy, hormonal therapy, immunotherapy, and targeted therapy.

To further improve the treatment outlook, there are approx. 100+ key companies developing therapies for Metastatic Breast Cancer. Currently, Roche is leading the therapeutics market with its Metastatic Breast Cancer drug candidates in the most advanced stage of clinical development.

Metastatic Breast Cancer Companies Actively Working in the Therapeutic Market Include:

Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc. Taizhou Hanzhong biomedical co. LTD, and many others.

Emerging and Marketed Metastatic Breast Cancer Drugs Covered in the Report Include:

  • Giredestrant: Roche

  • Disitamab Vedotin: RemeGen

  • EndoTAG®-1 (SB05): SynCore Biotechnology

  • Stenoparib (2X-121): Allarity Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Metastatic Breast Cancer Companies Working in the Market @

Analysis of Emerging Metastatic Breast Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Metastatic Breast Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Metastatic Breast Cancer Treatment Patterns

4. Metastatic Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Breast Cancer Late Stage Products (Phase-III)

7. Metastatic Breast Cancer Mid-Stage Products (Phase-II)

8. Metastatic Breast Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Breast Cancer Discontinued Products

13. Metastatic Breast Cancer Product Profiles

14. Major Metastatic Breast Cancer Companies in the Market

15. Key Products in the Metastatic Breast Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Metastatic Breast Cancer Unmet Needs

18. Metastatic Breast Cancer Future Perspectives

19. Metastatic Breast Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Hematuria Market

“Hematuria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hematuria market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hematuria market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States